Literature DB >> 3095111

The effect of verapamil on cardiovascular and metabolic responses to exercise.

H Petri, B G Arends, M A van Baak.   

Abstract

In a double-blind cross-over study, the effects of verapamil on the cardiovascular and metabolic changes during a progressive maximal exercise test were studied in 12 healthy volunteers. Each subject was treated with placebo and verapamil in 3 different dosages: 3 X 40, 3 X 80 and 3 X 120 mg X d-1 in random order. Drugs were administered for 2 days; on the 3rd day, 2 h after the last dose, a progressive exercise test until exhaustion was performed on a bicycle ergometer. No significant differences in maximal exercise capacity were found between the 4 groups of medication. VO2, VCO2, and VE were also unaffected by verapamil administration. Heart rate during exercise was reduced dose-dependently (p less than 0.001). With the highest dose of verapamil, maximal heart rate was reduced by 13 +/- 1 beats X min-1. No effect could be shown on parameters of carbohydrate and fat metabolism. Perceived exertion, estimated by the Borg scale, did not differ between placebo and the 3 medication groups. The study shows that despite a distinct reduction of heart rate, maximal exercise capacity remains unaffected after verapamil use.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095111     DOI: 10.1007/bf00421644

Source DB:  PubMed          Journal:  Eur J Appl Physiol Occup Physiol        ISSN: 0301-5548


  23 in total

1.  THE COLORIMETRIC MICRO-DETERMINATION OF NON-ESTERIFIED FATTY ACIDS IN PLASMA.

Authors:  W G DUNCOMBE
Journal:  Clin Chim Acta       Date:  1964-02       Impact factor: 3.786

2.  Pharmacokinetics of verapamil in patients with renal failure.

Authors:  J Mooy; M Schols; M v Baak; M v Hooff; A Muytjens; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Effect of beta-adrenoceptor blockade on exercise performance and metabolism.

Authors:  P Lundborg; H Aström; C Bengtsson; E Fellenius; H von Schenck; L Svensson; U Smith
Journal:  Clin Sci (Lond)       Date:  1981-09       Impact factor: 6.124

4.  [Metabolic and hormonal response to physical exercise under acute beta 1-adrenergic blockade (author's transl)].

Authors:  W Kindermann; W M Schmitt; G Biro; A Schnabel
Journal:  Z Kardiol       Date:  1981-05

Review 5.  Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.

Authors:  L H Opie
Journal:  Q J Med       Date:  1984

6.  Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients.

Authors:  C L van Herwaarden; R A Binkhorst; J F Fennis; A van't Laar
Journal:  Br Heart J       Date:  1979-01

7.  Serum concentration and antihypertensive effect of slow-release verapamil.

Authors:  E Schütz; H R Ha; F R Bühler; F Follath
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

8.  The place of the calcium antagonist verapamil in antihypertensive therapy.

Authors:  F R Bühler; U L Hulthén; W Kiowski; F B Müller; P Bolli
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

9.  Verapamil and propranolol in essential hypertension.

Authors:  A K Halperin; K M Gross; J F Rogers; L X Cubeddu
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

10.  Effects of acute and chronic metoprolol administration during submaximal and maximal exercise.

Authors:  M A van Baak; W Jennen; A Muijtjens; F T Verstappen
Journal:  Int J Sports Med       Date:  1985-12       Impact factor: 3.118

View more
  5 in total

1.  Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men.

Authors:  L Vanhees; R Fagard; A Amery
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

Review 2.  Perceived exertion. Antecedents and applications.

Authors:  B Watt; R Grove
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

Review 3.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 4.  Calcium antagonists and exercise performance.

Authors:  W Kindermann
Journal:  Sports Med       Date:  1987 May-Jun       Impact factor: 11.136

5.  A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes.

Authors:  Chih-Yuan Wang; Kuo-Chin Huang; Chia-Wen Lu; Chih-Hsun Chu; Chien-Ning Huang; Harn-Shen Chen; I-Te Lee; Jung-Fu Chen; Ching-Chu Chen; Chung-Sen Chen; Chang-Hsun Hsieh; Kai-Jen Tien; Hung-Yu Chien; Yu-Yao Huang; Jui-Pao Hsu; Guang-Tzuu Shane; Ai-Ching Chang; Yen-Chieh Wu; Wayne Huey-Herng Sheu
Journal:  J Clin Endocrinol Metab       Date:  2022-09-28       Impact factor: 6.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.